Bharat Parenterals Approves ₹139 Crore Preferential Issue to Institutional Investors
Bharat Parenterals Ltd · Outcome · 29 Sept 2026, 9:52 pm
Bharat Parenterals Approves ₹139 Crore Preferential Issue to Institutional Investors Bharat Parenterals' board approved a preferential allotment of up to 9,12,759 equity shares (face value ₹10) at ₹1,522.85 per share, raising ₹138.99 crore from 15 non-promoter investors, including WhiteOak Capital entities and Aurum Rising India Fund. Post-allotment, these investors will hold a combined 12.11% stake. The board also approved investing in or providing loans to subsidiaries for project development. An Extraordinary General Meeting is scheduled for 23rd Oct'26 to obtain shareholder approval for the proposed issue.
Original exchange filing (PDF)
More announcements from Bharat Parenterals Ltd
- Intimation for receipt of Establishment Inspection Report from US FDA by Innoxel Lifesciences Pvt Ltd., a subsidiary company of Bharat Parenterals Limited. · 05 Nov 2026
- Transcript of Earnings Conference Call of Q2FY27. · 02 Nov 2026
- Audio Recording of Q2FY27 Earnings Conference Call. · 30 Oct 2026
- Investor Presentation for the Quarter and Half Year ended on September 30, 2026. · 29 Oct 2026
- Un-Audited Standalone and Consolidated Financial Results For the Quarter and Half Year Ended On September 30, 2026. · 29 Oct 2026
- Outcome of the Meeting of the Board of Director of Bharat Parenterals Limited held on October 29, 2026 · 29 Oct 2026
- Approval of Preferential Issue by Shareholders of the Company through EGM Held on October 23, 2026. · 25 Oct 2026
- Revised Voting Result · 25 Oct 2026
